219 related articles for article (PubMed ID: 11816334)
1. [Polyarteritis nodosa and hepatitis B infection treated with lamivudine].
Münster T; Weis NM; Krogsgaard K
Ugeskr Laeger; 2002 Jan; 164(3):342-3. PubMed ID: 11816334
[TBL] [Abstract][Full Text] [Related]
2. Durability of serologic response after lamivudine treatment of chronic hepatitis B.
Dienstag JL; Cianciara J; Karayalcin S; Kowdley KV; Willems B; Plisek S; Woessner M; Gardner S; Schiff E
Hepatology; 2003 Apr; 37(4):748-55. PubMed ID: 12668966
[TBL] [Abstract][Full Text] [Related]
3. HBV-related cutaneous periarteritis nodosa in a patient 16 years after renal transplantation: efficacy of lamivudine.
Bedani PL; Bergami M; Cavazzini PL; Strumia R; Morelli MC; Stabellini G; Gilli P
J Nephrol; 2001; 14(5):428-30. PubMed ID: 11730280
[TBL] [Abstract][Full Text] [Related]
4. Lamivudine treatment for chronic hepatitis B infection in children unresponsive to interferon.
Hartman C; Berkowitz D; Shouval D; Eshach-Adiv O; Hino B; Rimon N; Satinger I; Kra-Oz T; Daudi N; Shamir R
Pediatr Infect Dis J; 2003 Mar; 22(3):224-9. PubMed ID: 12634582
[TBL] [Abstract][Full Text] [Related]
5. The duration of lamivudine therapy for chronic hepatitis B: cessation vs. continuation of treatment after HBeAg seroconversion.
Fung J; Lai CL; Tanaka Y; Mizokami M; Yuen J; Wong DK; Yuen MF
Am J Gastroenterol; 2009 Aug; 104(8):1940-6; quiz 1947. PubMed ID: 19455108
[TBL] [Abstract][Full Text] [Related]
6. Short-term corticosteroids then lamivudine and plasma exchanges to treat hepatitis B virus-related polyarteritis nodosa.
Guillevin L; Mahr A; Cohen P; Larroche C; Queyrel V; Loustaud-Ratti V; Imbert B; Hausfater P; Roudier J; Bielefeld P; Petitjean P; Smadja D;
Arthritis Rheum; 2004 Jun; 51(3):482-7. PubMed ID: 15188337
[TBL] [Abstract][Full Text] [Related]
7. [Chronic hepatitis B. Recent advances in diagnosis and treatment].
Bernardi M; Biselli M; Gramenzi A
Recenti Prog Med; 2002; 93(7-8):397-402. PubMed ID: 12138683
[TBL] [Abstract][Full Text] [Related]
8. Long-term follow-up of lamivudine treatment in patients with severe acute exacerbation of hepatitis B e antigen (HBeAg)-positive chronic hepatitis B.
Wong VW; Wong GL; Tsang SW; Hui AY; Chim AM; Yiu KK; Chan HY; Chan FK; Sung JJ; Chan HL
Antivir Ther; 2008; 13(4):571-9. PubMed ID: 18672536
[TBL] [Abstract][Full Text] [Related]
9. Beneficial effects of 'lamivudine pulse' therapy in HBeAg-positive patients with normal ALT*.
Sarin SK; Sandhu BS; Sharma BC; Jain M; Singh J; Malhotra V
J Viral Hepat; 2004 Nov; 11(6):552-8. PubMed ID: 15500556
[TBL] [Abstract][Full Text] [Related]
10. In vivo immunization by vaccine therapy following virus suppression by lamivudine: a novel approach for treating patients with chronic hepatitis B.
Horiike N; Fazle Akbar SM; Michitaka K; Joukou K; Yamamoto K; Kojima N; Hiasa Y; Abe M; Onji M
J Clin Virol; 2005 Feb; 32(2):156-61. PubMed ID: 15653419
[TBL] [Abstract][Full Text] [Related]
11. Long-term lamivudine monotherapy in renal-transplant recipients with hepatitis-B-related cirrhosis.
Viganò M; Colombo M; Aroldi A; Lunghi G; Manenti E; Ponticelli C; Lampertico P
Antivir Ther; 2005; 10(6):709-13. PubMed ID: 16218169
[TBL] [Abstract][Full Text] [Related]
12. Long-term lamivudine therapy for children with HBeAg-positive chronic hepatitis B.
Sokal EM; Kelly DA; Mizerski J; Badia IB; Areias JA; Schwarz KB; Vegnente A; Little NR; Gardener SD; Jonas MM
Hepatology; 2006 Feb; 43(2):225-32. PubMed ID: 16440364
[TBL] [Abstract][Full Text] [Related]
13. Effect of long-term lamivudine in chronic hepatitis B virus-infected children.
Ozgenç F; Arikan C; Sertoz RY; Nart D; Aydogdu S; Yagci RV
Antivir Ther; 2004 Oct; 9(5):729-32. PubMed ID: 15535410
[TBL] [Abstract][Full Text] [Related]
14. A three-month course of lamivudine therapy in HBeAg-positive hepatitis B patients with normal aminotransferase levels.
Yalçin K; Değertekin H; Kokoğlu OF; Ayaz C
Turk J Gastroenterol; 2004 Mar; 15(1):14-20. PubMed ID: 15264116
[TBL] [Abstract][Full Text] [Related]
15. Determinants for sustained HBeAg response to lamivudine therapy.
Chien RN; Yeh CT; Tsai SL; Chu CM; Liaw YF
Hepatology; 2003 Nov; 38(5):1267-73. PubMed ID: 14578866
[TBL] [Abstract][Full Text] [Related]
16. Genetic heterogeneity of the precore and the core promoter region of genotype C hepatitis B virus during lamivudine therapy.
Kuwahara R; Kumashiro R; Murashima S; Ogata K; Tanaka K; Hisamochi A; Hino T; Ide T; Tanaka E; Koga Y; Sata M
J Med Virol; 2004 Jan; 72(1):26-34. PubMed ID: 14635007
[TBL] [Abstract][Full Text] [Related]
17. Treatment of chronic hepatitis B with lamivudine.
Khokhar N; Gill ML; Alam AY
J Coll Physicians Surg Pak; 2005 Feb; 15(2):78-80. PubMed ID: 15730830
[TBL] [Abstract][Full Text] [Related]
18. A higher alanine aminotransferase level correlates with earlier hepatitis B e antigen seroconversion in lamivudine-treated chronic hepatitis B patients.
Tseng TC; Liu CJ; Wang CC; Chen PJ; Lai MY; Kao JH; Chen DS
Liver Int; 2008 Aug; 28(7):1034-41. PubMed ID: 18492018
[TBL] [Abstract][Full Text] [Related]
19. [Durability of HBeAg seroconversion in lamivudine treatment of chronic hepatitis B patients].
Zhu M; Xu B; Yao GB
Zhonghua Gan Zang Bing Za Zhi; 2005 Jul; 13(7):534-6. PubMed ID: 16042894
[TBL] [Abstract][Full Text] [Related]
20. Effect of lamivudine treatment in patients with decompensated cirrhosis due to anti-HBe positive/HBeAg-negative chronic hepatitis B.
Nikolaidis N; Vassiliadis T; Giouleme O; Tziomalos K; Grammatikos N; Patsiaoura K; Orfanou-Koumerkeridou E; Balaska A; Eugenidis N
Clin Transplant; 2005 Jun; 19(3):321-6. PubMed ID: 15877792
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
